Overall malformations in the angiotensin-converting enzyme inhibitor exposed group were 5.9% versus 3.3% in the unexposed. Adjusted analysis for confounding factors, such as diabetes, did not suggest an increase in the risk of malformations associated with the first trimester. The gene discussed is ACE; the disease is diabetes mellitus.